Novo Nordisk A/s

This study watches 200 adults in Japan with severe adult growth hormone deficiency who are taking Sogroya as part of their normal care. Researchers will track side effects and changes in body fat, muscle mass, and quality of life over 2 to 5 years. The goal is to see how safe and…

This study tests whether a new growth hormone medicine called somapacitan is safe and helps children grow taller. It includes children born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature. Participants receive a once-weekly injectio…

This study tests whether a weekly injection of semaglutide helps children and teenagers (ages 6 to under 18) with obesity or overweight lose weight. About 210 participants will receive either the drug or a placebo, plus lifestyle advice on diet and exercise, for up to 2.5 years. …

This study tests whether a monthly injection of ziltivekimab can reduce the risk of heart attacks, strokes, and heart-related death in 6,200 people who already have heart disease, chronic kidney disease, and signs of inflammation. Participants are randomly assigned to receive eit…

This study tests whether semaglutide, a diabetes drug, can help people with a serious fatty liver disease called NASH. About 1,200 adults with liver scarring but not cirrhosis will receive weekly injections of semaglutide or a placebo for up to 5 years. The goal is to see if the …

This study tests a new medicine, cagrilintide, to help people with overweight or obesity lose weight. About 300 adults will receive either the drug or a placebo for around 18 months. The main goal is to see how much weight they lose and how many achieve at least a 5% reduction.

This study tests a medicine called concizumab in children under 12 with hemophilia A or B, with or without inhibitors. The goal is to see if a daily injection under the skin can prevent bleeding episodes and be safe. About 153 children will take part for at least 2 years, using a…

This study tests whether semaglutide, a diabetes medicine, can slow or prevent diabetic eye disease over 5 years. About 1500 adults with type 2 diabetes will receive either semaglutide or a placebo injection once a week, alongside their usual diabetes care. The main goal is to se…

This study tests a once-weekly injection called CagriSema (a combination of two medicines) for weight loss and long-term weight maintenance in adults with obesity. About 600 participants will receive either CagriSema or a placebo for up to 3 years. The goal is to see if the treat…

This study tests a new medicine called concizumab for people with hemophilia A or B who do not have inhibitors. The goal is to see if a daily injection under the skin can prevent bleeding episodes safely. About 156 participants, aged 12 and older, will either start concizumab rig…

This study tests if a weekly injection called CagriSema (a mix of two drugs) can prevent heart attacks, strokes, and other heart-related deaths in people with established heart disease. About 7,100 participants will receive either CagriSema or a placebo for up to 4.5 years. The g…

This study looks at the long-term safety of an experimental medicine called NNC6019-0001 for people with transthyretin amyloid cardiomyopathy, a rare heart disease that can lead to heart failure. About 80 participants who completed a previous study will receive the medicine for u…

This study tests an experimental medicine called cagrilintide to see if it helps people with overweight or obesity and type 2 diabetes lose weight. About 330 adults will receive either the drug or a placebo for around 18 months. The main goals are to measure how much weight they …

This study follows 1250 people with obesity who are starting Wegovy as part of their regular care. Researchers will track weight, waist size, and quality of life over two years to see how the drug works in everyday life. The goal is to understand real-world effectiveness, not to …

This early-stage study tests a new injectable medicine for people who are overweight or have obesity. The main goal is to check if the medicine is safe and how the body handles it. About 63 participants will receive either the study drug or a placebo injection. This medicine is n…

This study follows 400 adults with growth hormone deficiency who are already taking Sogroya as part of their normal care. Researchers will collect information on side effects and effectiveness over 5 to 10 years. Participants will also fill out short questionnaires about their we…

This study follows 500 children with growth hormone deficiency who are already taking somapacitan (a weekly injection) to see how safe it is over the long term. Researchers will track side effects, medication errors, and whether any children develop new health issues like cancer …

This study follows about 728 pregnant women who took Wegovy for weight management and compares their outcomes to similar women who did not take the drug. Researchers will track birth defects and infant health through the first year of life. The goal is to better understand any ri…

This study looks at children and teenagers with growth hormone deficiency or who were born small for their age. It tracks how closely they follow their prescribed Norditropin treatment and whether that affects their final height. Researchers will collect data from up to 750 parti…

This study collects information from doctors and patient groups about haemophilia in Asia-Pacific countries. It aims to learn how many people have the condition, how often new cases occur, and what care is currently available. No treatments or medications are given—this is a surv…

This study is a registry that will follow about 221 children with Noonan Syndrome who are already taking or starting Norditropin® for short stature. Researchers will collect information on how the children grow over time, any side effects, and their quality of life. The goal is t…

This study examines the safety of taking Wegovy (semaglutide 2.4 mg) during pregnancy by analyzing insurance claims data from about 1,139 women. Researchers will compare pregnancy outcomes, such as birth defects and infant growth, between those exposed to Wegovy and those who wer…

This study gathers information from adults who have been prescribed injectable semaglutide for weight management. Participants complete online surveys about their health, weight changes, and quality of life. The study does not provide any treatment or collect lab data. It aims to…

This study follows 96 people with moderate Parkinson's disease to see how their symptoms change over time while taking their usual medications. Doctors may adjust treatments as needed. Participants will have up to 24 months of check-ups, including some where they temporarily stop…

This study follows 60 males with hemophilia B who are already taking the medication Refixia (also called REBINYN) to prevent bleeding. Researchers will track side effects, bleeding episodes, and quality of life over 4 to 9 years. Participants continue their usual care and clinic …